Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
alnylam pharmaceuticals
3
×
boston blog main
boston top stories
clinical trials
fda
life sciences
national blog main
national top stories
new york blog main
new york top stories
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
3
×
akcea therapeutics
boston
hereditary transthyretin amyloidosis
inotersen
patisiran
regeneron pharmaceuticals
tafamidis
vyndaqel
ambys medicines
amicus therapeutics
ampio pharmaceuticals
andrew fire
angelman syndrome
athenex
barry greene
biomarin pharmaceutical
biotech
bluebird bio
boston university
boulder/denver blog main
boulder/denver top stories
centers for medicare & medicaid services
chris collins
competitive generic therapy
craig mello
What
fda
3
×
alnylam
drug
medicine
patients
afternoon
ago
alnylam’s
approve
approved
aren’t
awaits
bio
biological
crossed
decades
decision
developers
discovered
drugs
fingers
friday
gene
gets
help
historic
history
imminent
landmark
long
making
medicare
moves
news
noteworthy
ok
onpattro
patisiran
pharmaceuticals
prices
Language
Current search:
photo
×
fda
×
" san francisco top stories "
×
" alnylam pharmaceuticals "
×
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
